Molina Healthcare Shares Plunge 27% on FDA Warning and Weak 2026 Outlook
Molina Healthcare shares plunged 27% after the FDA warned against illegal copycat drugs tied to its prescription plans. Earlier the stock had tumbled 29%, its worst since 2012, following an unexpected quarterly loss and below-consensus 2026 earnings guidance.
1. FDA Warning Impact
The FDA issued a caution on illegal copycat drugs purportedly covered under Molina’s Medicaid and Medicare plans, spurring a 27% one-day share collapse as investors weighed potential regulatory and liability risks.
2. Quarterly Results and Outlook
Molina reported an unexpected quarterly net loss and issued full-year 2026 earnings guidance below analyst estimates, signaling margin pressure from rising medical costs and challenging enrollment trends.
3. Historical Stock Reaction
Wednesday’s 29% drop marked the stock’s worst session since 2012, erasing over $2.5 billion in market value, as investors reassess growth assumptions amid regulatory scrutiny and profitability concerns.